Analysis of clinial variables associated with treatment efficacy of EGFR TKI in NSCLC EGFR-mutant patients.

Characteristics of included studies for indirect meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.Abbreviatio...

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Milella M
Nuzzo C
Sperduti I
Visca P
Buttitta F
Antoniani B
Merola R
Gelibter A
Cuppone F
D’Alicandro V
Ceribelli A
Rinaldi M
Cianciulli A
Felicioni L
Malatesta S
Marchetti A
Mottolese M
Cognetti F.
Bria, Emilio

January 2012

INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers t...

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie

January 2012

Background: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% ...

Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Analysis of clinical variables associated with progression free survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of H...

Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aHR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI...

Characteristics of included studies for direct meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.bHR19/...

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs

Jun CHEN
Hongyu LIU
Yuli WANG

April 2010

Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growt...

Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’

Paz-ares Et Al
J Cell
Mol Med
Claire Watkins
Yuri Rukazenkov

August 2016

Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene define a distinct s...

Profile summarizing the trial flow.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS ...

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

Milella, Michele
Nuzzo, Carmen
Bria, Emilio
Sperduti, Isabella
Visca, Paolo
Buttitta, Fiamma
Antoniani, Barbara
Merola, Roberta
Gelibter, Alain
Cuppone, Federica
D'Alicandro, Valerio
Ceribelli, Anna
Rinaldi, Massimo
Cianciulli, Anna
Felicioni, Lara
Malatesta, Sara
Marchetti, Antonio
Mottolese, Marcella
Cognetti, Francesco

April 2012

IntroductionThe optimal use of epidermal growth factor receptor (EGFR)-related molecular markers to ...

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations

Minjiang CHEN
Yan XU
Jing ZHAO
Wei ZHONG
Mengzhao WANG

February 2019

Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) hav...

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

Azuma, Koichi
Okamoto, Isamu
Kawahara, Akihiko
Taira, Tomoki
Nakashima, Kazutaka
Hattori, Satoshi
Kinoshita, Takashi
Takeda, Masayuki
Nakagawa, Kazuhiko
Takamori, Shinzo
Kuwano, Michihiko
Ono, Mayumi
Kage, Masayoshi

January 2012

IntroductionSomatic mutations in the epidermal growth factor receptor (EGFR) gene are associated wit...

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy

Milella M.
Nuzzo C.
Bria E.
Sperduti I.
Visca P.
Buttitta F.
Antoniani B.
Merola R.
Gelibter A.
Cuppone F.
D'Alicandro V.
Ceribelli A.
Rinaldi M.
Cianciulli A.
Felicioni L.
Malatesta S.
Marchetti A.
Mottolese Marcella.
Cognetti F.

January 2012

INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers t...

Characteristics of included studies for indirect meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.Abbreviatio...

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Milella M
Nuzzo C
Sperduti I
Visca P
Buttitta F
Antoniani B
Merola R
Gelibter A
Cuppone F
D’Alicandro V
Ceribelli A
Rinaldi M
Cianciulli A
Felicioni L
Malatesta S
Marchetti A
Mottolese M
Cognetti F.
Bria, Emilio

January 2012

INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers t...

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie

January 2012

Background: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% ...

Analysis of variables associated with overall survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Analysis of clinical variables associated with progression free survival in NSCLC EGFR-mutant patients.

Shih-Hsin Hsiao (106194)
H. Eugene Liu (501592)
Hsin-Lun Lee (501593)
Chii-Lan Lin (501594)
Wei-Yu Chen (316810)
Zhung-Han Wu (501595)
Sey-En Lin (382444)
Ling-Ling Chiang (501596)
Chi-Li Chung (106193)

December 2013

‡reference group was exon 21. EGFR: epidermal growth factor receptor, TKI: tyrosine kinase...

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of HR for PFS. CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

Direct comparison of TKI versus chemotherapy in EGFR exon 21 L858R mutations cohort in terms of H...

Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aHR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI...

Characteristics of included studies for direct meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.bHR19/...

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs

Jun CHEN
Hongyu LIU
Yuli WANG

April 2010

Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growt...

Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’

Paz-ares Et Al
J Cell
Mol Med
Claire Watkins
Yuri Rukazenkov

August 2016

Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene define a distinct s...

Profile summarizing the trial flow.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS ...

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

Milella, Michele
Nuzzo, Carmen
Bria, Emilio
Sperduti, Isabella
Visca, Paolo
Buttitta, Fiamma
Antoniani, Barbara
Merola, Roberta
Gelibter, Alain
Cuppone, Federica
D'Alicandro, Valerio
Ceribelli, Anna
Rinaldi, Massimo
Cianciulli, Anna
Felicioni, Lara
Malatesta, Sara
Marchetti, Antonio
Mottolese, Marcella
Cognetti, Francesco

April 2012

IntroductionThe optimal use of epidermal growth factor receptor (EGFR)-related molecular markers to ...

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations

Minjiang CHEN
Yan XU
Jing ZHAO
Wei ZHONG
Mengzhao WANG

February 2019

Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) hav...

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

Azuma, Koichi
Okamoto, Isamu
Kawahara, Akihiko
Taira, Tomoki
Nakashima, Kazutaka
Hattori, Satoshi
Kinoshita, Takashi
Takeda, Masayuki
Nakagawa, Kazuhiko
Takamori, Shinzo
Kuwano, Michihiko
Ono, Mayumi
Kage, Masayoshi

January 2012

IntroductionSomatic mutations in the epidermal growth factor receptor (EGFR) gene are associated wit...

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy

Milella M.
Nuzzo C.
Bria E.
Sperduti I.
Visca P.
Buttitta F.
Antoniani B.
Merola R.
Gelibter A.
Cuppone F.
D'Alicandro V.
Ceribelli A.
Rinaldi M.
Cianciulli A.
Felicioni L.
Malatesta S.
Marchetti A.
Mottolese Marcella.
Cognetti F.

January 2012

INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers t...

Characteristics of included studies for indirect meta-analysis.

Yaxiong Zhang (629676)
Jin Sheng (629677)
Shiyang Kang (629678)
Wenfeng Fang (172072)
Yue Yan (522296)
Zhihuang Hu (522294)
Shaodong Hong (629679)
Xuan Wu (126953)
Tao Qin (177288)
Wenhua Liang (110687)
Li Zhang (8200)

September 2014

aExon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.Abbreviatio...

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Milella M
Nuzzo C
Sperduti I
Visca P
Buttitta F
Antoniani B
Merola R
Gelibter A
Cuppone F
D’Alicandro V
Ceribelli A
Rinaldi M
Cianciulli A
Felicioni L
Malatesta S
Marchetti A
Mottolese M
Cognetti F.
Bria, Emilio

January 2012

INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers t...

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Wang, Fen
Wang, Shuhang
Wang, Zhijie
Duan, Jianchun
An, Tongtong
Zhao, Jun
Bai, Hua
Wang, Jie

January 2012

Background: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% ...

Analysis of clinial variables associated with treatment efficacy of <i>EGFR</i> TKI in NSCLC <i>EGFR</i>-mutant patients.

Abstract

Extracted data

Analysis of clinial variables associated with treatment efficacy of <i>EGFR</i> TKI in NSCLC <i>EGFR</i>-mutant patients.

Abstract

Extracted data

Related items

Related items